OncoMatch/Clinical Trials/NCT06846268
Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer
Is NCT06846268 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including ADG126 and Pembrolizumab for locally advanced colorectal cancer.
Treatment: ADG126 · Pembrolizumab — This is a single site, open-label, single-arm phase II study to determine feasibility, tolerability, and preliminary efficacy of neoadjuvant ADG126 and pembrolizumab in stage II or III colorectal cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Disease stage
Required: Stage II, III
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: radiation therapy
Prior radiation therapy ... for colorectal cancer
Cannot have received: chemotherapy
Prior ... chemotherapy ... for colorectal cancer
Cannot have received: immunotherapy
Prior ... immunotherapy ... for colorectal cancer
Cannot have received: surgery
Prior ... surgery for colorectal cancer
Lab requirements
Blood counts
ANC ≥ 1,500/mcL; Platelets ≥ 100,000/mcL; Haemoglobin ≥ 9 g/dL
Kidney function
Serum creatinine ≤ 1.5 x ULN OR creatinine clearance ≥ 60 mL/min for subjects with creatinine > 1.5 x ULN
Liver function
Serum total bilirubin ≤ 1.5 x ULN OR Direct bilirubin ≤ ULN for subjects with total bilirubin > 1.5 x ULN. AST and ALT ≤ 2.5 x ULN.
Demonstrate adequate organ function as defined below ... Haematological: ANC ≥ 1,500/mcL; Platelets ≥ 100,000/mcL; Haemoglobin ≥ 9 g/dL. Renal: Serum creatinine ≤ 1.5 x ULN OR creatinine clearance ≥ 60 mL/min for subjects with creatinine > 1.5 x ULN. Hepatic: Serum total bilirubin ≤ 1.5 x ULN OR Direct bilirubin ≤ ULN for subjects with total bilirubin > 1.5 x ULN. AST and ALT ≤ 2.5 x ULN. Coagulation: INR ≤ 1.5 or PT ≤ 1.5 x ULN; and either PTT or aPTT ≤ 1.5 x ULN. Patients on warfarin may be included on a stable dose with a therapeutic INR < 3.5.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify